JDD

Innovative Hyperpigmentation Solutions: Insights from Our Latest Research

Retrieved on: 
Thursday, February 22, 2024
Pigment, JDD, Hyperpigmentation, Journal

In the realm of hyperpigmentation, the quest for more effective and safer options for prevalent and often stubborn pigmentary disorders is ongoing.

Key Points: 
  • In the realm of hyperpigmentation, the quest for more effective and safer options for prevalent and often stubborn pigmentary disorders is ongoing.
  • The latest publication in the Journal of Drugs in Dermatology (JDD), February 2024 issue, presents a groundbreaking study that could change the paradigm in the field of hyperpigmentation solutions.
  • The study, led by a team of distinguished pigmentation experts across the globe, introduces a novel dermatological approach that promises equal efficacy to the gold standard with a rapid onset of action and enhanced patient satisfaction.

Innovative Hyperpigmentation Solutions: Insights from Our Latest Research

Retrieved on: 
Thursday, February 22, 2024
Pigment, JDD, Hyperpigmentation, Journal

In the realm of hyperpigmentation, the quest for more effective and safer options for prevalent and often stubborn pigmentary disorders is ongoing.

Key Points: 
  • In the realm of hyperpigmentation, the quest for more effective and safer options for prevalent and often stubborn pigmentary disorders is ongoing.
  • The latest publication in the Journal of Drugs in Dermatology (JDD), February 2024 issue, presents a groundbreaking study that could change the paradigm in the field of hyperpigmentation solutions.
  • The study, led by a team of distinguished pigmentation experts across the globe, introduces a novel dermatological approach that promises equal efficacy to the gold standard with a rapid onset of action and enhanced patient satisfaction.

VI Peel® Announces 36% Boost in Anti-Aging Benefits of Botox® from New Clinical Study

Retrieved on: 
Tuesday, February 13, 2024
Pain, Acne, Melasma, ALL, RN, Patient satisfaction, Ageing, JDD, Skin, MBA, Hyperpigmentation, Habit, Patient, Smash Mouth, FAAD, Trial of the century, Cosmetics

"The efficacy of VI Peel and Botox same-day treatment was clinically proven by the improvements to wrinkle severity, uniformity of pigment, and skin tone via photographic matching," Roberts says.

Key Points: 
  • "The efficacy of VI Peel and Botox same-day treatment was clinically proven by the improvements to wrinkle severity, uniformity of pigment, and skin tone via photographic matching," Roberts says.
  • "The clinical significance of this combination will appeal to multi-generational patients where anti-aging and skin health remain at the forefront of their buying habits."
  • This is in direct contrast to the majority of medical or clinical studies that favor Caucasians or lighter Fitzpatrick types.
  • A ToxBooster Treatment combines a VI Peel followed immediately by a Neurotoxin Injection (like Botox®, Xeomin®, Dysport®, Juveau® and Daxxify®).

Novan Announces Publication of Psoriasis Patient Data Demonstrating Need for Rapid Symptom Improvement¹

Retrieved on: 
Thursday, April 27, 2023
Cream, National Psoriasis Foundation, Wake Forest School of Medicine, JDD, MC2, Novin, Scalp, Vitamin D, Psoriasis, Journal, Patient, Physician, Calcipotriol, Therapy, Pharmaceutical industry, Dermatology, Medicine

DURHAM, N.C. and COPENHAGEN, Denmark, April 27, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), and MC2 Therapeutics today announced that results of a recently conducted survey to assess psoriasis patients’ topical treatment experience, expectations, and preferences have been published in the Journal of Drugs in Dermatology (JDD). The survey was conducted by the National Psoriasis Foundation and was sponsored by the Company. Most of the participants self-reported having moderate psoriasis (83.9%); most were using systemic therapies (73.5%) and employing topical medications at least once per week (84%).

Key Points: 
  • The survey was conducted by the National Psoriasis Foundation and was sponsored by the Company.
  • Most of the participants self-reported having moderate psoriasis (83.9%); most were using systemic therapies (73.5%) and employing topical medications at least once per week (84%).
  • Understanding what factors impact adherence can help guide physicians in our choice of topical psoriasis treatments.” commented Steven R. Feldman, M.D., Ph.D., Professor of Dermatology, Wake Forest University School of Medicine.
  • “Findings from this survey demonstrated that psoriasis patients expect to see rapid improvement of their symptoms, or they report they will discontinue topical treatment.

JDD Studio Renovates International Institute of Minnesota, Prepares for Open House

Retrieved on: 
Wednesday, June 22, 2022
Population, Institute, International Institute of Minnesota, Student, Lunch, New, Workforce, IIMN, Rest, Refugee, Multimedia, JDD, Interior design, New Americans

ST. PAUL, Minn., June 22, 2022 /PRNewswire/ -- JDD Studio had the great pleasure of partnering with the International Institute of Minnesota (IIMN) on the renovation of the IIMN headquarters.

Key Points: 
  • ST. PAUL, Minn., June 22, 2022 /PRNewswire/ -- JDD Studio had the great pleasure of partnering with the International Institute of Minnesota (IIMN) on the renovation of the IIMN headquarters.
  • "The impact of the Institute on the lives of Minnesota's refugee and immigrant population cannot be underestimated.
  • "JDD Studio helped the Institute dream upa space that honors the experiences of New Americans when they come to Minnesota.
  • JDD Studio has extensive experience in concept design, programming, master planning, architectural design, interior design, and in supporting capital campaigns.

WebMD Health Corp. Acquires SanovaWorks, Building on Leadership in Medical Education

Retrieved on: 
Tuesday, January 25, 2022
Steps, Patient, Internet Brands, Conference, Journal, Publication, WebMD, HCPS, JDD, Growth, Textilease/Medique 300, Temasek, CEO, Health, Front line, RxList, Acquisition, Skin, Heart, KKR, EMedicine, Home & Travel, SMB, Multimedia, PulsePoint, Surgery, Physician, Freedom of Establishment and Freedom to Provide Services in the European Union, Medicine, Online shopping, Medscape, Jeffrey A. Krames, MedicineNet, Color, Review, Dermatology

In addition, SanovaWorks offers the online and audio-format Derm in Review, a board certification and recertification course.

Key Points: 
  • In addition, SanovaWorks offers the online and audio-format Derm in Review, a board certification and recertification course.
  • WebMD, an Internet Brands company, is at the heart of the digital health revolution that is transforming the healthcare experience for consumers, patients, healthcare professionals, employers, health plans and health systems.
  • The WebMD Health Network includes WebMD Health, Medscape, Jobson Healthcare Information, MediQuality, Frontline, Vitals Consumer Services, Aptus Health, Krames, PulsePoint, The Wellness Network, MedicineNet, eMedicineHealth, RxList, OnHealth, Medscape Education, and other owned WebMD sites.
  • WebMD, Medscape, CME Circle, Medpulse, eMedicine, MedicineNet, theheart.organd RxList are among the trademarks of WebMD Health Corp. or its subsidiaries.

Nuveen Multi-Asset Income Fund Declares Initial Distribution

Retrieved on: 
Monday, November 29, 2021
Professional Services, Finance, JTA, Life, Policy, NAV, TIAA, JDD, NMAI, Time, Solution, Income, Nuveen, Indian Sugar Mills Association, Security (finance), Life insurance, Risk management

Historical distribution sources have included net investment income, realized gains and return of capital.

Key Points: 
  • Historical distribution sources have included net investment income, realized gains and return of capital.
  • If a distribution includes anything other than net investment income, the fund provides a notice of the best estimate of its distribution sources at that time which may be viewed at www.nuveen.com/CEFdistributions .
  • Under a managed distribution policy, Nuveen closed-end funds seek to maintain a stable regular distribution amount that, over the long term, matches the funds total distributions paid to its total return.
  • Nuveen and the closed-end funds managed by Nuveen and its affiliates undertake no responsibility to update publicly or revise any forward-looking statement.

Nuveen Announces Completion of Multi-Asset Closed-End Fund Reorganizations

Retrieved on: 
Monday, November 22, 2021
Professional Services, Finance, New, JTA, JTD, JDD, NMAI, Income, NYSE, Financial services, Bank

The reorganizations of Nuveen Diversified Dividend and Income Fund (NYSE: JDD), Nuveen Tax-Advantaged Total Return Strategy Fund (NYSE: JTA), and Nuveen Tax-Advantaged Dividend Growth Fund (NYSE: JTD) into a new fund, Nuveen Multi-Asset Income Fund (NYSE: NMAI), was successfully completed prior to the opening of the New York Stock Exchange on November 22, 2021.

Key Points: 
  • The reorganizations of Nuveen Diversified Dividend and Income Fund (NYSE: JDD), Nuveen Tax-Advantaged Total Return Strategy Fund (NYSE: JTA), and Nuveen Tax-Advantaged Dividend Growth Fund (NYSE: JTD) into a new fund, Nuveen Multi-Asset Income Fund (NYSE: NMAI), was successfully completed prior to the opening of the New York Stock Exchange on November 22, 2021.
  • The combined fund, NMAI, seeks to provide total return through high current income and capital appreciation, employing a dynamic multi-asset allocation strategy that is designed to improve diversification and take into account changing market conditions.
  • The exchanges took place based upon the acquired funds closing net asset values on November 19, 2021 and NMAIs initial net asset value per common share of $20.
  • The exchange ratios at which common shares of each acquired fund were exchanged for common shares of NMAI are listed below:

Nuveen Multi-Asset Funds Announce Shareholder Approval of Reorganization Proposal

Retrieved on: 
Thursday, October 14, 2021
Professional Services, Finance, NYSE, JTD, Indian Sugar Mills Association, NMAI, TIAA, JDD, Solution, Income, JTA, Nuveen, Financial services

Shareholders of Nuveen Diversified Dividend and Income Fund (NYSE: JDD), Nuveen Tax-Advantaged Total Return Strategy Fund (NYSE: JTA) and Nuveen Tax-Advantaged Dividend Growth Fund (NYSE: JTD) have approved a proposal to reorganize the funds.

Key Points: 
  • Shareholders of Nuveen Diversified Dividend and Income Fund (NYSE: JDD), Nuveen Tax-Advantaged Total Return Strategy Fund (NYSE: JTA) and Nuveen Tax-Advantaged Dividend Growth Fund (NYSE: JTD) have approved a proposal to reorganize the funds.
  • The funds are anticipated to begin transitioning their portfolio prior to the reorganization, with additional portfolio transition occurring after the reorganization is complete.
  • Nuveen is a leading sponsor of closed-end funds (CEFs) with $65 billion of assets under management across 62 CEFs as of 30 June 2021.
  • Nuveen and the closed-end funds sponsored by Nuveen undertake no responsibility to update publicly or revise any forward-looking statements.

Journal of Drugs and Dermatology Publishes Clinical Study on Topix Pharmaceuticals, Inc. New Vitamin C E +  green Tea Polyphenols Serum

Retrieved on: 
Tuesday, September 21, 2021
Health, Cosmetics, Retail, Pharmaceutical, Specialty, Elasticity, Ergothioneine, John Foster Dulles, TOPIX, Serum, Self-assessment, JDD, GTP, Achievement, Ageing, Apigenin, Patient, Patient satisfaction, Medication, Physician, MD, Complex, Vitamin E, Tooth discoloration, Environment, Twitter, CEO, Skin care, Antioxidant, Trial of the century, Absorption, Science, Journal, View, Oxidative stress, Research, VP, Vitamin C, Light, Vitamin, OXO-biodegradation, Skin, Pharmaceutical industry, Dietary supplement

Offered by dermatologists, plastic surgeons and medical aestheticians nationwide, Topix Vitamin C E + Green Tea Polyphenol (GTP) serum is the most cutting edge vitamin C formulation, offering dispensing physicians and their patients a much-needed update to Vitamin C technologies that have been around for decades.

Key Points: 
  • Offered by dermatologists, plastic surgeons and medical aestheticians nationwide, Topix Vitamin C E + Green Tea Polyphenol (GTP) serum is the most cutting edge vitamin C formulation, offering dispensing physicians and their patients a much-needed update to Vitamin C technologies that have been around for decades.
  • In clinical trials, the Vitamin CE + GTP Serum showed significant increases in skin density, statistical improvements in multiple aesthetic parameters and positive patient satisfaction (n=31).
  • In 12 weeks:
    The Topix Vitamin C E + GTP Serum delivers the first pharmaceutical approach to antioxidant therapy and long-lasting formula stability, potency and efficacy (2+ years).
  • Dr. Jared Jagdeo MD MS says, Vitamin C E + GTP is a potent formula combination that delivers proven impactful clinical results.